Outcomes of switching from crizotinib to alectinib in patients with advanced non-small cell lung cancer with anaplastic lymphoma kinase fusion

BACKGROUND: Alectinib and crizotinib have been approved as first-line therapies for advanced non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) gene fusion. However, the therapeutic efficacy and side effects are still largely unknown of patients who switched to next-generation...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Yingying, Xiao, Wenjing, Ye, Feng, Wang, Huijuan, Shen, Yihong, Yu, Xinmin, Han, Xiao, Chu, Qian, Zhou, Caicun, Zhang, Zhihong, Ren, Shengxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267309/
https://www.ncbi.nlm.nih.gov/pubmed/34277814
http://dx.doi.org/10.21037/atm-21-2769

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267309/
https://www.ncbi.nlm.nih.gov/pubmed/34277814
http://dx.doi.org/10.21037/atm-21-2769

Ejemplares similares